FDA’s Update on Biosimilars and Interchangeability Status for BLAs
Biologicals are booming as therapy and have significantly become an established treatment option to provide ailment to niche disease segments which seemed impossible earlier. COVID-19 pandemic has made researchers keen to develop biosimilar and interchangeable products for the patient population at an affordable price. The procedure to attain a biosimilar and interchangeable status is rigorously structured by the FDA to ensure that the quality of the preparation remains significantly unchanged.